Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Dahej plant EIR response expected September; management optimistic given only 2 relatively insignificant observations. Indrad plant re-inspection date not yet communicated by FDA. Until clearances, US portfolio remains niche and profitable focus.
Dahej approvals face 'big queue' at FDA. Revlimid launch timing unclear—late entrant with settlement terms undisclosed. Management explicitly deprioritized US as capital allocation target versus India/branded emerging markets.
Novo Nordisk has undertaken inventory rationalization since Q4, impacting Torrents B2B insulin manufacturing revenues. Expected to recover in about a quarter, but near-term headwind to 'others' segment.
Q1 acute sales weaker across most datasets. Torrents ~INR 1,000 crore gastro business impacted by seasonality, though chronic business grew double digits. Recovery expected in coming months.
